Human cardiac-muscle patches made from Cardiomyocyte produced from induced pluripotent stem cells can mimic the genetics of individual patients and thus be utilised for drug testing, disease modelling, and therapeutic applications. Traditional hCMPs, on the other hand, are rather thin and include iCMs that have the structure and function of fetal Cardiomyocyte [1]. We constructed thicker, triple-layered hCMPs using our layer-by-layer fabrication method, and then assessed iCM maturity after ten days of standard culture, static stretching, or stretching with electrical stimulation at 15 or 22 V. Stretched+22V increased contractile protein expression and alignment, according to stained hCMPs, whereas measurement of mRNA abundance and protein expression revealed that Stretched+22V increased bimolecular maturation. Images taken using a transmission electron microscope revealed that Animal models have traditionally been used for disease modelling and medication testing . Researchers have been able to conduct in vitro investigations on a totally human platform because to the discovery of tools for producing tissues from human induced pluripotent stem cells Argentati Molinari and Sayer. Cardiomyocytes derived from hiPSCs fully duplicate all genetic elements that may impact the genesis and course of cardiac disease in a particular patient, as well as the patient's response to treatment, because hiPSCs may be reprogrammed from each patient's own somatic cells. Conventional manufacturing procedures, on the other hand, often create thin human cardiac muscle patches, whereas hiPSC-CMs are physically and functionally more akin to CMs.